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Huntingtin cleavage product A forms in neurons
and is reduced by gamma-secretase inhibitors
Kimberly B Kegel1*, Ellen Sapp1, Jonathan Alexander1, Patrick Reeves1, Dorothee Bleckmann2, Linsday Sobin1,
Nicholas Masso1, Antonio Valencia1, Hyunkyung Jeong1, Dimitri Krainc1, James Palacino3, Daniel Curtis3,
Rainer Kuhn2, Claudia Betschart4, Miguel Sena-Esteves1, Neil Aronin5, Paolo Paganetti2, Marian DiFiglia1
Abstract
Background: The mutation in Huntington’s disease is a polyglutamine expansion near the N-terminus of
huntingtin. Huntingtin expressed in immortalized neurons is cleaved near the N-terminus to form N-terminal
polypeptides known as cleavage products A and B (cpA and cpB). CpA and cpB with polyglutamine expansion
form inclusions in the nucleus and cytoplasm, respectively. The formation of cpA and cpB in primary neurons has
not been established and the proteases involved in the formation of these fragments are unknown.
Results: Delivery of htt cDNA into the mouse striatum using adeno-associated virus or into primary cortical
neurons using lentivirus generated cpA and cpB, indicating that neurons in brain and in vitro can form these
fragments. A screen of small molecule protease inhibitors introduced to clonal striatal X57 cells and HeLa cells
identified compounds that reduced levels of cpA and are inhibitors of the aspartyl proteases cathepsin D and
cathepsin E. The most effective compound, P1-N031, is a transition state mimetic for aspartyl proteases. By western
blot analysis, cathepsin D was easily detected in clonal striatal X57 cells, mouse brain and primary neurons,
whereas cathepsin E was only detectible in clonal striatal X57 cells. In primary neurons, levels of cleavage product
A were not changed by the same compounds that were effective in clonal striatal cells or by mRNA silencing to
partially reduce levels of cathepsin D. Instead, treating primary neurons with compounds that are known to inhibit
gamma secretase activity either indirectly (Imatinib mesylate, Gleevec) or selectively (LY-411,575 or DAPT) reduced
levels of cpA. LY-411,575 or DAPT also increased survival of primary neurons expressing endogenous full-length
mutant huntingtin.
Conclusion: We show that cpA and cpB are produced from a larger huntingtin fragment in vivo in mouse brain
and in primary neuron cultures. The aspartyl protease involved in forming cpA has cathepsin-D like properties in
immortalized neurons and gamma secretase-like properties in primary neurons, suggesting that cell type may be a
critical factor that specifies the aspartyl protease responsible for cpA. Since gamma secretase inhibitors were also
protective in primary neurons, further study of the role of gamma-secretase activity in HD neurons is justified.
Background
Huntington disease (HD) is caused by an expansion of a
normal CAG repeat in the gene encoding the protein
huntingtin [1]. The CAG repeat is translated into a
polyglutamine (Q) tract near the N-terminus of hunting-
tin, which is 3144 amino acids (aa) in length. Patients
that bear this mutation suffer neurodegeneration result-
ing in cognitive and personality changes early in the
disease, and later develop an overt movement disorder
characterized by chorea, rigidity, and dysphagia. HD is
eventually fatal. Brains of HD patients show atrophy of
the cortex and profound cell loss in the striatum. The
exact cause of neuronal dysfunction and cell death is
not clear.
Compelling evidence points to a role for N-terminal
huntingtin fragments with an expanded polyQ tract
(mutant huntingtin) in HD pathogenesis. In human HD
post-mortem tissue, cytoplasmic and nuclear inclusions
were exclusively recognized by antibodies to epitopes
within the N-terminus of huntingtin [2]. Similarly,
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N-terminal huntingtin fragments shorter than 342 aa
were identified by epitope mapping in degenerating neu-
rons in the brain of HD knock-in mice (HdhCAG150)
which express endogenous mutant huntingtin [3]. These
stable fragments of mutant huntingtin appear pre-symp-
tomatically as early as 2 weeks postnatal, suggesting
their formation precedes the onset of disease in mice
[4]. Mutant N-terminal huntingtin fragments expressed
in mouse brain and in cells form inclusions and cause
toxicity [5-11]. Transgenic mice over-expressing short
N-terminal huntingtin fragments including huntingtin
aa1-89 [5] or huntingtin aa1-171 [12] develop a motor
phenotype and some neuropathological features
observed in human HD patients. Moreover, these two
HD mouse models show earlier onset of symptoms and
have more severe phenotypes than transgenic mice
expressing larger fragments [13] or full-length mutant
huntingtin [14-16]. The length of huntingtin fragment
does not dictate toxicity, however, since shorter frag-
ments are not consistently more toxic than larger frag-
ments. For example, exogenous expression of mutant
huntingtin aa1-208 showed more toxicity than hunting-
tin aa1-89 in transfected cells [3]. Similarly, in mice a
transgene expressing mutant huntingtin aa1-119 called
“short stop” generates inclusions without a motor phe-
notype [17] although animals expressing a longer frag-
ment (aa1-171) do develop motor symptoms [12]. Thus,
proteolysis of full-length huntingtin at particular sites
may be necessary to produce toxicity.
Huntingtin is a substrate for multiple proteases and
cleavage within its N-terminus could form specific toxic
fragments. There are cleavage sites in huntingtin for dif-
ferent caspases (caspase 2,3 and 6), calpain, cathepsin D
and thrombin within 600 residues from the N-terminus
[18-21]. Studies suggest that unique protease products
of mutant huntingtin are harmful in vivo. Caspase 6
cleavage in mutant huntingtin at amino acid 586 has
been identified as a potential source of toxic mutant
huntingtin fragments in vivo. HD transgenic mice
(Yac128) expressing full-length mutant huntingtin with
a point mutation at the 586 cleavage site are protected
from motor deficits and neuropathology [22]. In con-
trast, the Yac128 HD transgenic mouse with a point
mutation at 552, the caspase 2/3 cleavage site, still
develops neuropathology and motor deficits [22]. The
results suggest that the caspase-6 product (huntingtin
aa1-586) is toxic whereas the caspase-2/3 product (hun-
tingtin aa1-552) is not.
Smaller N-terminal cleavage products (cp) of mutant
huntingtin known as cpA and cpB were first identified
in cultured immortalized neurons over-expressing larger
N-terminal huntingtin fragments or full-length mutant
huntingtin [23]. Treating cells with proteasome inhibi-
tors increased levels of the fragments. The accumulation
of cpA and cpB in the presence of proteasome inhibitors
may have relevance to the progressive and age depen-
dent nature of HD, since proteasome activity decreases
with normal aging [4]. The exact cleavage sites are
unknown, but biochemical analysis and epitope mapping
suggest that cpA is < 115 aa and cpB is < 214aa [23].
Deletion analyses support this conclusion: deletion of
huntingtin aa104-114 impaired generation of cpA
whereas deletion of huntingtin aa205-215 impaired for-
mation of cpB [23,24]. Immunolabeling studies revealed
that cpA can enter the nucleus and localize to intranuc-
lear inclusions; CpB is excluded from the nucleus likely
due to its larger size and instead is detected in cytoplas-
mic inclusions [23]. In mice, the addition of a nuclear
localization signal to mutant htt 1-89 accelerates onset
and progression of disease [25]; thus a proteolytic event
in neurons that creates a huntingtin fragment in a simi-
lar size range such as cpA may hasten pathology in
humans. In view of this, it is imperative to determine
whether cpA and cpB occur in neurons and identify
effective protease inhibitors that could have therapeutic
benefits. It is not known if cpA or cpB can be detected
in primary neurons and in the absence of proteasome
inhibition. Moreover, the protease(s) involved in forming
cpA and cpB have not been identified; however, some
evidence indicates that an aspartyl protease, possibly
cathepsin D, was responsible for cpA using a cell-free in
vitro assay [23,24].
In this study we used viral delivery of truncated hun-
tingtin into primary neurons and into brain to deter-
mine if neurons generate cpA and cpB. We also
screened a focused library of protease inhibitors to iden-
tify the protease(s) involved in generating these frag-
ments. Our findings suggest that neurons are capable of
forming cpA and cpB in vivo and that an aspartyl pro-
tease activity generates cpA.
Results
CpA and cpB form in neurons in vivo and in vitro
Small molecular weight cleavage products of huntingtin
in the range of cpA or cpB have been identified in brain
lysates from human control and HD brain [6,26], in
transgenic mice over-expressing huntingtin aa1-171 [2]
and in HD knock-in mice expressing Q150/Q150 [24].
It is unclear if the fragments detected in brain lysates
correspond to cpA and cpB and if they form in neurons
or in glia, the non-neuronal cells of the brain. To
address this directly, we injected mouse striatum with
adeno-associated virus (AAV) vector encoding cDNA
for truncated wild-type huntingtin (htt1-400-18Q) or
mutant huntingtin (htt1-400-100Q) (Figure 1). We used
cDNA encoding truncated huntingtin because viral vec-
tors cannot accommodate encoded full-length hunting-
tin cDNA ( > 9 kb); also levels of N-terminal huntingtin
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fragments expressed from the endogenous full-length
huntingtin are difficult to detect even in the presence of
proteasome inhibitors. Recent studies showed that hun-
tingtin aa1-400 delivered by AAV is expressed in striatal
and cortical neurons and not in non-neuronal cells and
causes neuropathology and a motor deficit [11]. Bio-
chemical analysis of striatal lysates from brain infected
with AAV expressing htt1-400-18Q and htt1-400-100Q
revealed proteolytic products of the expected size for
cpA (25 kDa for wild-type and 50-55 kDa for mutant)
and cpB (35-40 kDa from wild-type and 60 kDa from
mutant) (Figure 2a, b). Note that polyQ expansion slows
the migration of intact and cleaved huntingtin on SDS-
PAGE. An intermediate band was also detected with
htt-400-100Q as previously described [24]. The products
were absent in control (uninfected) brains. To confirm
the products in brain were cpA and cpB, we compared
the migration of the fragments from the brain lysates
with lysates from HeLa cells expressing htt1-400-100Q
treated without or with the proteasome inhibitor epoxo-
micin (5 μM), which increased levels of cp A and cpB in
the cultured cells (Figure 2c). In AAV-infected mouse
brains expressing htt1-400-100Q, proteolytic products
migrated similarly to cpA and cpB in HeLa cells. These
data show that cpA and cpB accumulate in neurons in a
mouse model of HD.
To establish that cpA and cpB also formed in neurons
in vitro, we infected rat primary striatal neurons with
different concentrations of lentivirus encoding htt1-400-
18Q or 1-400-100Q. We used rat embryos instead of
mouse embryos since the striata of rat embryos is tech-
nically easier to dissect and yields more neurons. After
two weeks in culture, huntingtin fragments migrating at
the size of cpA and cpB were detected by western blot
in lysates of the infected primary striatal neurons; the
levels of the fragments increased with increasing con-
centration of virus (Figure 2d). We also observed cpA
and cpB in cortical rat neurons infected with lentivirus
htt1-400-100Q after two weeks in culture, and the frag-
ments were enhanced by treatment with 5 μM epoxomi-
cin applied 4 hours prior to harvest (Figure 2e). With
epoxomicin, levels of cpB increased 52.4% compared to
DMSO alone and levels of cpA increased 37.6% com-
pared to DMSO alone (P < 0.05, n = 3, unpaired t test).
Based on deletion analysis, huntingtin truncation to
amino acid 171 should result in formation of cpA but
not cpB [23,24]. We infected primary mouse cortical
neurons with lentivirus containing cDNAs encoding
huntingtin aa1-171 (18Q and 100Q) driven by a PGK
promoter. Previous study has shown that use of PGK
promoter is more effective than CMV promoter for len-
tiviral infection of mutant huntingtin in neurons [27]. In
primary mouse cortical neurons infected with lenti-
PGK-htt1-171 (18Q and 100Q), the intact expressed
protein and the protease product cpA were detected
from 2-9 days post-infection in the absence of epoxomi-
cin (Figure 2f). Levels of htt171-18Q and htt171-100Q
accumulated from 2 to 4 days post infection. However
at 9 days post-infection, levels of intact htt171-100Q
continued to increase whereas levels of htt171-18Q had
peaked and decreased (Figure 2f). CpA continually
formed from htt171-18Q but was produced more slowly
from htt171-100Q. CpA also formed in primary rat neu-
rons infected with Lenti-PGK-htt1-171 (18Q & 100Q)
and was detectible in the absence of epoxomicin (not
shown). These studies suggest that cpA and cpB form in
neurons in brain and in vitro. Detection of cpA and
cpB production in neurons in brain and in vitro did
not require addition of proteasome inhibitors. More-
over, mutant htt171-100Q may resist cleavage and
degradation.
Cell-based screen for inhibitors of wild-type huntingtin
cpA and cpB
The aspartyl protease inhibitor pepstatin A was found
effective in partially reducing levels of cpA in vitro in
cell-free digestion assays or in immortalized neuronal-
like cells when used at 100 μM but had no effect on
cpB [23,24]. Pepstatin A inhibits a broad spectrum of
aspartyl proteases and is poorly cell permeable and
therefore not a reliable inhibitor for cell based studies.
Since the protease for cpB was also unknown, we per-
formed a cell-based assay to find soluble compounds
that inhibit cpA and/or cpB production (Additional File
1 Figure S1). Compounds with inhibitory properties
against specific aspartyl proteases were included in the
screen. Clonal striatal (X57) cells are immortalized cells
formed from a fusion of mouse neuroblastoma and
mouse embryonic striatum [28] and were used for the
screen due to the large number of compounds. We tran-
siently transfected X57 cells with htt1-287-18Q with a
Figure 1 Schematic of huntingtin protein. Schematic shows
locations of epitope for Ab1 antibody (aa1-17) and mAb 2B7 (aa1-
17) and the polyglutamine region (black box). Membrane binding is
contributed by aa1-17 [44], the poly-proline region (gray box, [45])
and aa172-372 (white box, [62]). Regions of calpain and caspase
cleavage are represented by arrows. Approximate regions of cpA
and cpB cleavage are also marked by arrows. Shown below are
three huntingtin cDNA constructs used in this study.
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Figure 2 Primary neurons in culture and in brain produce and accumulate cpA from over-expressed htt1-400. (a, b) Western blot shows
lysates from striatum of 3 mice injected with AAV-htt1-400-18Q and 4 mice injected with AAV-htt1-400-100Q probed with anti-huntingtin
antibody Ab1. Arrowheads show the expressed, intact htt1-400-18Q (a) and htt1-400-100Q (b), and arrows indicate cpA and cpB. Short unlabeled
arrow indicates an intermediate band (b). For (a) 4-12% Bis-Tris gel and full-length huntingtin serves as a loading control, and for (b) 4-20% Tris-
glycine gel and blot was reprobed with tubulin as a loading control. (c) Lysates from infected mouse brain striatum were also analyzed on the
same gel as lysates from HeLa cells expressing htt400-100Q ± the proteasome inhibitor epoxomicin (EPX) to identify cpA and cpB from mouse
brain. SDS-PAGE run on 10% Tris-glycine gel. (d) Western blots of lysates from primary rat striatal neurons treated with lentivirus delivering
cDNAs encoding htt1-400-18Q or htt1-400-100Q. Concentration of lentivirus in multiplicity of infection (moi) indicated at top. Arrowhead, intact
htt1-400; arrows, cpA and cpB, open arrowhead, non-specific band. 4-12% Bis-Tris gels. (e) Western blots of lysates from primary rat cortical
neurons treated with lentivirus (80 moi) delivering cDNAs encoding htt1-400-100Q. Arrowhead, intact htt1-400; arrows, cpA and cpB; open
arrowhead, non-specific band. 3-8% Tris-acetate gel. Cells were treated with 5 M epoxomicin (EPX) or carrier (DMSO) for final 4 hours. (f) Western
blots of lysates from primary cortical mouse neurons infected with lentivirus-PGK-htt1-171 (18Q or 100Q) then harvested post-infection at days
indicated. Lysates from uninfected control “C” neurons are shown for comparison. Arrowheads, intact expressed protein; arrows indicate cpA. For
171-100Q, an intermediate band is also visible. 4-12% Bis-Tris gel for 18Q and 3-8% Tris-acetate gel for 100Q. Samples were run on the same gel,
white line indicates removal of lanes.
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C-terminal HA tag (H287-18Q-HA) and treated with
epoxomicin for the final 6 hours to increase the levels
of cpA and cpB (Figure 3a) as described by [24]. We
screened a focused library of 102 proprietary com-
pounds known to inhibit different families of proteases.
Compounds were screened at 10 μM. 17 hits represent-
ing 5 major categories of proteases were identified that
inhibited cpA and/or cpB production by > 50% (Addi-
tional File 2 Table S1). Of the 17 primary hits, only
three compounds showed dose-responsive inhibition of
cpA (one example illustrated in Figure 3). All three
were inhibitors of aspartyl proteases (Table 1 and Figure
4). The most effective compound in cells, P1-N031,
shows the highest specificity for cathepsin E and greater
specificity for human cathepsin D compared to BACE1,
BACE2, or (porcine) pepsin measured using in vitro
enzyme assays (Table 1). A gamma secretase inhibitor
was also included and was not effective in the screen
with clonal striatal cells. We also expressed htt1-287-
18Q-HA in a human cell line (HeLa) and detected cpA.
Aspartyl protease inhibitors were effective at inhibiting
cpA formed in HeLa cells. However, the inhibitors that
reduced levels of cpA in HeLa cells differed from those
identified using X57 cells. Compound P1-N039, which is
highly effective at blocking both cathepsin D and cathe-
psin E, reduced cpA in HeLa cells, whereas compounds
P1-N031 and P1-N034 were not effective in HeLa cells
(data not shown). The other inhibitors effective in HeLa
cells were specific for cathepsin D over cathepsin E. No
hits were identified that inhibited cpB production in a
dose-responsive manner.
Cell-free screen to detect inhibitors of huntingtin
cpA and cpB
Previous studies showed that in a cell-free assay of
huntingtin cleavage, pepstatin A blocked formation of
cpA [23,24]. In this assay, the crude nuclear pellet
containing lysosomes, ER and other membranes, as well
as expressed huntingtin protein is isolated from cells
and after adjusting the pH to 3.5, allowed to self-digest
for 1 hour at 37°C. We performed a cell-free assay using
lysates from X57 or HeLa cells expressing H287-
18Q-HA. Two compounds that inhibited cpA in X57
cells in the cell-based screen (P1-N031 and P1-N039)
were effective in reducing levels of cpA in the cell-free
assay (Additional File 1 Figure S2a, b). The same com-
pounds inhibited cpA-like fragments in digested HeLa
cell lysates expressing H287-18Q-HA or mutant htt1-
400-100Q (compare Additional File 1 Figure S2b and c).
Both P1-N031 and P1N039 preferentially inhibit
cathepsin D and cathepsin E in purified in vitro enzyme
assays. Compound P1-N038, which has a greater specifi-
city for BACE1 and BACE2 (Table 1), failed to inhibit
cpA formation in the self-digestion assay and in the
cell-based assay. The findings in the cell-free assay sup-
port the results in the cell-based assay and suggest that
the aspartyl protease responsible for creating cpA from
huntingtin in clonal striatal cells is related to cathepsin
D or cathepsin E.
Effects of selected aspartyl protease inhibitors on cpA
production in primary neurons and evaluation of
cathepsin D as the responsible protease
We tested if the aspartyl protease inhibitors that inhib-
ited cpA in X57 cells were also effective in reducing
cpA production in rodent primary neurons. We used
lenti-htt1-171-18Q, which produces cpA (Figure 2f), to
test compounds in primary rat and mouse neurons. We
examined in primary neurons the three compounds that
were effective in clonal striatal X57cells (P1-N031,
Figure 3 Compound P1-N031 shows dose-dependent inhibition
of cpA in X57 cells. (a) Example western blot of lysates from clonal
striatal cells transfected with H287-18Q-HA and treated with small
molecule P1-N031 (Novartis) or carrier (DMSO). Arrowhead identifies
the intact htt1-287-HA and arrows show cpA and cpB. The
compound P1-N031 inhibits in a dose-dependent manner levels of
cpA, but not cpB. (b) Dose-response curves for cpA (solid line) and
cpB (dashed line). Y-axis is densitometry of ratio of signal for
protease fragment relative to intact Htt1-287 to average DMSO. X-
axis is concentration of compound in μM. Error bars represent sd, *
p < 0.05, Friedman’s test with Dunn’s multiple comparison post-test
(N = 3 /dose).
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P1-N034, P1-N039). Primary cortical neurons from rat
exposed to several of the compounds at 3-10 μM
showed morphological features of cell death including
blebbing, cell body shrinkage and detachment from the
dish. This occurred in the absence of infection with len-
tivirus-htt1-171. Therefore, we treated cells with 1 μM,
which did not produce these toxic changes. Compounds
were introduced into rat neurons 18 hours after infec-
tion with lentivirus-htt1-171-18Q. We also evaluated the
effects of the compounds in mouse neurons with the
same protocol and by pre-treating with compounds 18
hours before infection with lentivirus. None of the com-
pounds were effective at inhibiting cpA in neurons at
1 μM in either of the experimental paradigms tested
(data not shown). We also treated neurons with 100 μM
pepstatin A or a peptide inhibitor of cathepsin D
(10 μM H-GEG), both of which prevent accumulation
of cpA in clonal striatal X57 cells [24]. These two inhi-
bitors were not toxic but were ineffective in inhibiting
cpA in neurons. These results show that none of the
aspartyl protease inhibitors with high specificity for
cathepsin D were effective in primary neurons.
Western blot analysis confirmed that cathepsin D is
expressed in clonal striatal X57 cells, in brain and in pri-
mary neurons whereas cathepsin E was only detectible
in X57 cells and at very low levels in primary neurons
(Additional File 1 Figure S3). We introduced a siRNA
targeting cathepsin D to reduce levels of cathepsin D
protein in mouse primary neurons; mRNA silencing
partially reduced protein levels of cathepsin D but had
no effect on levels of cpA (Additional File 1 Figure S4).
Together with the results above using cathepsin D inhi-
bitors, these findings suggest that cathepsin D is not the
aspartyl protease responsible for cleavage of huntingtin
to generate cpA in primary neurons.
Modulators and inhibitors of gamma-secretase reduce
levels of cpA in primary neurons
We found a different set of aspartyl protease inhibitors
was effective in clonal striatal cells versus HeLa cells.
Thus, we speculated that the protease cleaving cpA may
differ among cell types. Despite the fact that an inhibitor
of the aspartyl protease, gamma secretase, was among
the compounds that failed to affect cpA in clonal striatal
Table 1 Selectivity of inhibitors against cpA production in clonal striatal X57 cells (EC50) compared to selectivity
against purified aspartic proteases (IC50) in μM
Compound Human Htt cpA
EC50
Human BACE1
IC50
Human BACE2
IC50
Human Cathepsin D
IC50
Human Cathepsin E
IC50
Porcine Pepsin
IC50
P1-N031 0.2 5.5 3.1 0.018 0.0002 0.29
P1-N034 4.9 < 0.0005 0.0006 ~0.5 0.002 0.79
P1-N038 > 10 0.007 0.014 0.52 0.81 0.14
P1-N039 1.3 0.003 0.003 0.0006 0.0002 0.0002
Figure 4 The chemical structures for select aspartyl proteases.
Compounds P1-N031, P1-N034 and P1-N039 were effective at
inhibiting cpA in clonal striatal cells. Compound P1-N031 has
greater specificity for cathepsin D and cathepsin E compared to
BACE 1 and BACE 2 whereas compound P1-N038 which was
ineffective at blocking cpA has greater specificity for BACE 1 and
BACE 2 (see also Table 1).
Kegel et al. Molecular Neurodegeneration 2010, 5:58
http://www.molecularneurodegeneration.com/content/5/1/58
Page 6 of 16
cells, we thought gamma secretase could be a candidate
for generating cpA in neurons. Gamma-secretase is
expressed in neurons and is associated with membranes
where huntingtin is also localized [29]. With this in
mind, we tested compounds known to inhibit gamma-
secretase in primary neurons. The kinase inhibitor ima-
tinib mesylate (Gleevec) retards production of beta-
amyloid from amyloid precursor protein through effects
on gamma-secretase [30,31]. We tested whether cpA
levels were affected by Gleevec. Primary neurons were
infected with lenti-htt1-171-18Q and treated with
Gleevec at 0.1 μM and 0.03 μM. Gleevec significantly
reduced levels of cpA compared to treatment with
DMSO carrier alone (Figure 5a, b). These findings show
that the protease responsible for cleaving huntingtin to
produce cpA can be modulated by Gleevec. We also
tested two specific inhibitors of gamma secretase that
are mechanistically distinct: LY-411575 [32] and DAPT
[33]. We found that LY-411575 inhibited cpA produc-
tion in primary neurons (Figure 5c, d). Treatment with
0.1 μM DAPT was also effective at inhibiting cpA pro-
duction in primary neurons (Figure 5e,f). These results
Figure 5 Modulators and inhibitors of gamma secretase reduce CpA levels produced from htt171-18Q in primary mouse neurons.
(a) Western blot of lysates from neurons treated with Gleevec for 18 hours then infected with lentiPGK-ht171-18Q and cultured an additional 24
hours. Arrows indicates the over-expressed huntingtin fragment (Intact) and the cleavage product, cpA. Blots were re-probed with beta-3-tubulin
to control for total neuron protein. (b) Densitometry results from western blot analysis of Gleevec treatment. Levels of cpA were significantly
reduced in cultures treated with indicated concentrations compared treatment with DMSO solvent alone. One way ANOVA, p < 0.03, * p < 0.05
Dunnett’s Multiple comparison test, n = 3 for DMSO and n = 3 for treatment conditions. (c) Western blot of lysates from neurons infected with
lentiPGK-ht171-18Q for 18 hours then treated with LY-411,575 and cultured an additional 24 hours. Arrows indicates the over-expressed
huntingtin fragment (Intact) and the cleavage product, cpA. Blots were re-probed with beta-3-tubulin to control for total neuron protein.
(d) Densitometry results from western blot analysis of LY-411,575 treatment. Levels of cpA were significantly reduced in cultures treated with
indicated concentrations compared treatment with DMSO solvent alone. One way ANOVA, p < 0.003, * p < 0.05 Dunnett’s Multiple comparison
test, n = 3 for DMSO and n = 3 for treatment conditions. (e) Western blot of lysates from neurons infected with lentiPGK-ht171-18Q for 18 hours
then treated with DAPT at 0.01 μM and cultured an additional 24 hours. Arrows indicates the over-expressed huntingtin fragment (Intact) and
the cleavage product, cpA. Blots were re-probed with beta-3-tubulin to control for total neuron protein. (f) Densitometry results from western
blot analysis of DAPT treatment. Levels of cpA were significantly reduced in cultures treated with indicated concentrations compared treatment
with DMSO solvent alone. * p < 0.05, n = 3 for DMSO and n = 3 for treatment conditions, paired t-test.
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suggest that gamma-secretase is responsible for cpA
production in primary cortical neurons.
We examined the effects of a cell free source of
gamma-secretase activity on huntingtin proteolysis.
SY5Y cells are reported to contain functionally active
gamma-secretase complex [34]. After 2 or 5 hours incu-
bation with a CHAPSO-soluble membrane fraction of
SY5Y cells prepared according to Li et al. [35], there
was no proteolysis of immunopurified FLAG-huntingtin
171-18Q (Fhtt171-18Q) observed (results not shown).
Gamma-secretase inhibitors increase survival
of HD primary neurons
Previously we showed reduced survival of HD primary
neurons homozygous for a knock-in of 140 CAGs
(Q140/Q140) at 10 DIV [36,37]. We questioned whether
gamma secretase inhibition could reduce mutant hun-
tingtin-dependent toxicity. First we used immunopreci-
pitation assay to look for evidence of small N-terminal
fragments in Q140/Q140 primary cortical neurons since
this method enhances detection of small N-terminal
fragments generated from full-length huntingtin [24,38].
Following immunoprecipitation of huntingtin with
monoclonal antibody (mAb) 2B7 against huntingtin
1-17 [39], fragments in the size range expected for cpA
and cpB bearing a 140Q repeat were detected on wes-
tern blots probed with polyclonal Ab1 against hunting-
tin 1-17 (Figure 6a). Having established the presence of
small huntingtin fragments in HD primary neurons, we
treated wild-type (WT) or HD cortical neurons with
gamma-secretase inhibitors at 4DIV using a concentra-
tion (0.1 μM) that had previously reduced levels of cpA
about 50%. Neuronal viability was measured by MTT
assay at DIV 10. Both DAPT and LY-411,575 conferred
significant protection to HD neurons (Figure 6b). LY-
411,575 was slightly toxic to WT neurons under the
prolonged treatment conditions (from 4DIV to 10DIV).
Long-term treatment of WT primary neurons with
Gleevec resulted in neurite retraction, possibly due to
blockade of PI 3-kinase dependent signaling pathways,
and thus was not evaluated in HD neurons. To ascertain
if the increased survival in the presence of gamma secre-
tase inhibitors correlated with reduced proteolysis of
huntingtin, we treated neurons with DAPT or DMSO
from 4 DIV to 10 DIV then immunoprecipitated full-
length huntingtin and fragments using mAb 2B7. Wes-
tern blots of immunoprecipitates probed with Ab1
showed a lower level of two mutant huntingtin frag-
ments: one in the size range of cpA with a 140Q (~ 80
kDa) and a higher band at ~100 kDa (Additional File 1
Figure S5). When standardized to the amount of full-
length mutant huntingtin pulled down, the fragments
from neurons treated with DAPT were at levels of 30%
and 41% of DMSO for the 100 kDa band and 80 kDa
band, respectively using densitometry. These results show
that small fragments are produced in primary neurons
expressing full-length endogenous mutant huntingtin and
reduced levels of huntingtin fragments may mediate pro-
tective effects of gamma-secretase inhibitors.
Discussion
Small N-terminal fragments of mutant huntingtin may be
pathogenic in HD. In this study we sought to establish
Figure 6 Inhibitors of gamma-secretase protect primary
cortical HD neurons homozygous for full-length mutant
huntingtin (Q140/Q140) from cell death. (a) Immunoprecipitation
(IP) of mutant huntingtin from 23 DIV neurons using a monoclonal
antibody against htt1-17 (mAb2B7) and probed with polyclonal anti-
htt1-17 (Ab1). Arrow indicates full-length huntingtin when IP is
performed with mAb2B7 while the control lanes are blank. N-
terminal fragments were detected at ~100 kDa and ~80 kDa. Small
blot on right is the enlargement of the second and third IP lanes
with the double-sided arrow indicating a fragment ~72 kDa. The
predicted mobility of cpA with 140Q ranges from ~69 kDa to ~85
kDa. (b) Graph shows MTT conversion reported as mean percentage
of wild-type (WT) neurons treated with carrier (DMSO) ±SD. One-
way ANOVA, p < 0.001, Bonferroni’s Multiple comparison tests: *
over bar indicates p < 0.001 for WT vs HD, *p < 0.001 compared to
HD treated with DMSO, †p < 0.001 compared to WT treated with
DMSO.
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that huntingtin fragments cpA and cpB can form in neu-
rons and to identify the protease(s) involved in formation
of cpA and cpB in neurons. We found that cpA and cpB
are detected in neurons and in mouse brain, under con-
ditions where truncated wild-type or mutant huntingtin
are over-expressed. Levels of cpA formed from truncated
huntingtin in immortalized clonal striatal cells were
diminished by inhibitors of aspartyl proteases selective for
cathepsin D and cathepsin E. In primary neurons, cpA
production was inhibited by Gleevec, a known modulator
of beta-amyloid production and by the specific gamma-
secretase inhibitors LY-411,575 and DAPT. Gamma-
secretase inhibitors also increased survival of HD neu-
rons. These findings suggest that the source of aspartyl
protease activity required for cpA production may be cell
specific and that gamma secretase activity may have a
pathogenic role in HD through formation of cpA.
In the present study as in previous studies the addi-
tion of a proteasome inhibitor to immortalized cells
expressing truncated huntingtin greatly enhanced detec-
tion of cpA and cpB. This suggests that these fragments
are normally at low levels and are cleared very rapidly
by the proteasome [23,24]. We were able to detect cpA
and cpB in primary neurons and in the brain without
the addition of proteasome inhibitors using expression
of truncated huntingtin. These data suggest that the
levels of cpA and cpB are more stable in neurons in
vitro than in immortalized cells. Proteasome activity is
higher in glia than in neurons [40]. It is possible that
basal proteasome activity in immortalized neuronal cells
is greater than in neurons because they are a fusion of
neurons and glia. Previous investigators have speculated
that N-terminal huntingtin fragments similar in size to
cpA and cpB may accumulate in neurons due to a
decline in proteasome function that occurs with normal
aging [4].
Our study is the first to use a focused library of small
compounds in a cell-based screen to identify a protease
involved in huntingtin processing. The compounds con-
tained in this library include inhibitors for several
families of proteases namely cysteine proteases (calpain,
caspases, cathepsins), serine proteases (thrombin/tryp-
sin/chymotrypsin, kallikrein, and DPP), metalloproteases,
aspartyl proteases, and the proteasome. Inhibitors span-
ning five protease families reduced cpB or cpA at 10
μM in the primary screen; however, only a small num-
ber of the aspartyl protease inhibitors attenuated cpA
production in subsequent dose-dependent analysis in
our cell-based assay. Our results support the conclusion
that cpA is generated directly by an aspartyl protease.
Indirect or non-specific effects on huntingtin cleavage
may have accounted for the inhibition of cpA and cpB
by non-aspartyl protease inhibitors in the initial cell
based screen. The small compound hits proved toxic in
neurons at comparable dilutions to those used in clonal
striatal cells (X57 cells). Immortalized cells might be
protected because they may express the multi-drug
resistance pump, which can pump toxic moieties out of
the cell. We used a self-digestion assay to verify the
results of our cell-based screen. The huntingtin frag-
ments in the self-digestion assay varied slightly in size
compared to cpA accumulating in cells [4,23,24]. We
suggest that these variations in size of the fragments
between the two assays are most likely due to post-
translational modifications such as ubiquitination [23]
and not due to a difference in the protease since the
same compounds were effective in both the cell-free and
the cell-based assays.
Compound P1-N031 was the most effective in block-
ing cpA production in immortalized clonal striatal cells;
this compound is an aspartyl protease transition state
mimetic and has high specificity for cathepsin D and
cathepsin E using in vitro enzyme assays. We conclude
that in immortalized clonal striatal cells (X57 cells) hun-
tingtin is subject to proteolysis by an aspartyl protease
with properties similar to cathepsin D or cathepsin
E. We cannot rule out a role for both cathepsin D and
cathepsin E in cpA production in X57 cells, since these
cells were enriched in both proteases.
To our surprise we found that three inhibitors of
gamma-secretase activity reduced cpA levels in primary
neurons. Gamma-secretase is a multiprotein complex
expressed in neurons with aspartyl protease activity that
localizes to the plasma membrane [41]. All known
gamma-secretase substrates are type I integral mem-
brane proteins [42]. Huntingtin does not contain a pre-
dicted transmembrane domain but does associates with
membranes including plasma membranes through elec-
trostatic and hydrophobic interactions via a membrane
association domain at aa172-373 [43]. Regions within
huntingtin aa1-89 (exon1) can also bind and insert into
synthetic lipid bilayers [43-45] and increased polygluta-
mine length may increase membrane association and
bilayer insertion [46]. Polyglutamine stretches can form
pores in lipid bilayers [47], thus the polyglutamine
region might mimic a transmembrane domain. Proteoly-
sis by gamma-secretase generally occurs after removal of
an ectodomain in the substrate by another protease or
“sheddase” [48]. Huntingtin is cleaved at several sites
distal to the cpA site: from aa453-586 by caspases, at
~aa400 by calpains and a metalloprotease, and by an
unknown protease to create cpB (see Figure 1). Proteo-
lysis at any of these sites might be analogous to ectodo-
main “shedding” leaving a short piece of huntingtin
tightly associated with, and perhaps partially inserted
into, the membrane. This may trigger a signal for pro-
teolytic degradation by gamma-secretase [48]. It is also
possible that huntingtin may be exposed to the catalytic
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pocket of gamma secretase at the aqueous surface of the
membrane where protease activity is also speculated to
occur [49]. We observed that mutant huntingtin resists
cleavage consistent with another report [50]. Decreased
flexibility of the polyglutamine and polyproline stretch
in mutant huntingtin could impede entry of the peptide
into the active site. The signal peptide peptidases, a
related family of peptidases to gamma secretase, are
intramembrane peptidases that are sensitive to com-
pounds that affect gamma-secretase activity and could
be responsible for cpA production. However, DAPT,
which inhibited cpA production, does not affect their
activity [51]. Recently an unbiased screen of siRNAs that
target proteases identified eleven proteases that when
knocked down reduced the production of a small hun-
tingtin N-terminal fragment through cleavage at a more
distal site [21]; one of these proteases, IMP5/signal pep-
tide peptidase-like candidate protease 2C (SPPL2c) is
related to gamma-secretase and might also produce
cpA. It is possible that cpA is generated by another
protease whose activation requires gamma-secretase
activity. Gamma-secretase may liberate a C-terminal
domain from a protein such as APP or Notch that
induces transcription of the responsible protease, or
gamma-secretase may directly activate another protease
by removing its prodomain. A gamma-secretase cleavage
assay failed to cleave htt1-171 -18Q. However, gamma-
secretase activity can be modulated by substrate-specific
activating factors [52] that may not be present in SY5Y
cells and by specific phospholipids [53] which were not
added to our reaction; one or more of these factors may
be required for optimal activity against huntingtin.
Thus, further studies will be required to discern direct
or indirect roles of gamma-secretase activity in htt clea-
vage and minimal conditions for proteolysis.
We found two inhibitors of gamma-secretase activity
are neuroprotective in HD140Q/140Q neurons. Our
data also show that neuroprotection by one of these
inhibitors (DAPT) was associated with reduced levels of
two mutant huntingtin fragments one of which was con-
sistent with the size of cpA. These findings implicate
inhibition of a toxic fragment in neuroprotection. How-
ever, gamma-secretase inhibitors affect other signaling
pathways such as calcium signaling [54]; thus, neuropro-
tection provided by gamma secretase inhibitors could
also involve mechanisms unrelated to mutant htt
processing.
Prior to its identification, gamma-secretase was
described as an aspartyl protease with cathepsin D-like
properties based on the ability of some peptidomimetic
probes to inhibit both gamma-secretase activity and
cathepsin D [55]. We found active cathepsin D in pri-
mary cortical neurons. However, compounds known to
inhibit cathepsin D and genetic knockdown of the
protease using siRNA failed to affect levels of cpA, sup-
porting a conclusion that cathepsin D is not the respon-
sible enzyme for cpA in neurons. One caveat to this
conclusion is that we could only achieve 38% reduction
in the levels of cathepsin D compared to the non-target
siRNA control condition. Cathepsin D normally may be
at saturating levels such that partial knockdown (38%)
still shows no effect on cpA. One would still expect
cathepsin D inhibitors to block cpA formation which we
did not observe. In contrast to cathepsin D, we did not
detect cathepsin E in 8-10 week old mouse brain lysates
or in primary neurons. Previous studies showed that
cathepsin E is undetectable in rat brain from young
animals (2 months) or found only in microglia of rats at
20 months, but is detected in neurons with advancing
age (34 months [56]). Thus, in primary neurons, cathe-
psin E activity is also unlikely to be the protease gener-
ating cpA.
It is formally possible that the aspartyl protease activ-
ity involved in cpA production is an autoproteolytic
activity of huntingtin. Aspartyl proteases use two aspar-
tates within their active sites and presenilin-1 has been
shown to undergo endoproteolysis that requires two of
its aspartates [57]. Huntingtin contains 6 aspartates
(D100, D139, D140, D144, D150, and D162) within the
first 171 amino acids that could form an active site.
Self-digestion assays with purified MBP-tagged hunting-
tin failed to generate cpA (our unpublished observa-
tions) arguing against an autocatalytic property.
Our data suggest that the aspartyl protease responsible
for cpA may be cell type specific. We found cathepsin
D/cathepsin E like aspartyl proteases more effective in
clonal striatal cells and Hela cells and gamma secretase
more effective in neurons. It is likely that cathepsin D
and gamma secretase are present in all cell types. It is
unclear what accounts for this variation. Cell type speci-
fic differences in intracellular targeting of the expressed
htt and access to available protease may be involved.
Expression levels of htt may be much higher with transi-
ent transfection into fewer proliferating cells than with
lentivirus-mediated delivery into neurons where exogen-
ous protein is present at lower levels in most neurons.
High levels of expressed huntingtin fragment induce
autophagy and increase the activity of cathepsin D in
clonal striatal cells [58]. We suggest that proteases iden-
tified to cleave htt in cell lines need to be validated by
analysis of neurons.
The primary sites of cleavage for generating cpA or
cpB have not been determined despite deletion analysis
and alanine scanning efforts. Deletion of huntingtin
104-114 [23] and 108-113 [24] blocked cpA production
in cells however it is still not clear whether this is the
actual site of cleavage or a so-called “docking site” for
the enzyme. Compound P1-N031 is an aspartyl protease
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transition state mimetic and as such might be useful to
predict the primary site of cleavage within huntingtin.
Unfortunately, results from a comparison of P1-N031 to
structural predictions for the polypeptide region in hun-
tingtin 101-115 did not reveal the primary site of clea-
vage. We and others have tried unsuccessfully to obtain
enough purified product to determine the cleavage site
by mass spectrometry. Using western blot analysis and
epitope mapping, the smallest detectible fragment gener-
ated from full-length huntingtin in PC12 cells or from
knock-in mice or was the size of exon 1 (aa1-89)
[59,60]. Interestingly, this would place the site of clea-
vage at a group of charged polar amino acids immedi-
ately adjacent to a membrane-binding region [43-45]
consistent with the hypothesis that huntingtin may slip
into the catalytic pocket of presenilin if it is exposed to
the aqueous environment [49].
Our studies did not reveal a protease involved in
forming cpB. Although inhibitors from five protease
families, including aspartyl proteases were effective in
reducing cpB, none were effective in follow-up dose
response analysis. We also found no compounds in our
screen that inhibited cpB but not cpA. If cpA and cpB
are generated from the same enzyme, it could be argued
that cpB is required for cpA formation. In this scenario,
inhibition of both cleavages to the same degree would
result in no effective change in cpB levels, since reduced
formation of cpB would be balanced by reduced break-
down of cpB to cpA. Alternatively, our assay design may
not be optimal for detecting inhibition of cpB since
much more cpB is produced from huntingtin 1-287
compared to cpA. Finally, compounds most effective for
cpB inhibition may not have optimal permeability char-
acteristics to access intracellular compartments where
cleavage may occur.
Conclusion
We have shown that small N-terminal huntingtin frag-
ments known as cpA and cpB are generated in neurons
in brain and primary neuron cultures and do not require
additional inhibition of the proteasome to accumulate. A
cell-based screen of protease inhibitors showed that the
enzyme producing cpA is an aspartyl protease and in
primary neurons it is likely to be gamma-secretase or a
highly related enzyme. CpA formed in primary neurons
using viral delivery of huntingtin aa 1-171. It is note-
worthy that a cleavage product the size of cpA is
detected in brain of transgenic mice expressing mutant
huntingtin aa1-171 with polyglutamine expansion [2].
Given that some mutant huntingtin fragments may be
innocuous and others harmful, it will be necessary in
future studies to identify the sizes of cpA and cpB in
order to determine whether expression of these frag-
ments in the brain is toxic to neurons. Targeting the
appropriate enzymes responsible for generating toxic
fragments is likely to be a useful therapeutic target for
HD. Unfortunately, gamma-secretase inhibitors have
toxic side effects in peripheral tissues [32]. Therefore,
study of the effects of modulators of gamma-secretase
activity on huntingtin proteolysis may be more useful.
Methods
Compounds
Compounds were delivered as powders and resuspended
in DMSO to a final dilution of 10 mM and stored at
room temperature (RT) until further dilution. The pro-
prietary compounds were coded blinding scientists to
both structure and enzyme specificity. Gleevec (imatinib
mesylate) was resuspended in 90% DMSO/10%H20 to a
stock concentration of 10 mM; LY-411,575 [32] and
DAPT [33] were prepared as described and made solu-
ble in the same carrier.
Enzymatic activity assays
Enzymes were prepared as described [61] or obtained
from R & D systems (Cathepsin D and Cathepsin E).
Fluorescent assays to measure cleavage activity were
performed as described [61].
Cell-Based Assay
Cells, plasmids and transfections: X57 cells are an
immortalized clonal striatal cell line made by fusion of
E18 striatal neurons and N18TG2 neuroblastoma cells
[28]. HeLa cells were obtained from American Type
Culture Collection and grown using their recommenda-
tions. The X57 cells were grown at 37°C and 5% CO2 in
Dulbecco’s modified Eagle medium (DMEM) with high
glucose and containing 10% fetal bovine serum (FBS),
penicillin/ streptomycin and glutamine. X57 cells were
transiently transfected with the pcDNA3 vector with an
insertion of the cDNA encoding huntingtin aa1-287
with 18Q and a C-terminal HA tag (pcDNA3-htt287-
18Q-HA) or huntingtin aa1-400 with 18Q or 100Q
(pcDNA-htt400-18Q and pcDNA-htt400-100Q). For cell
transfections in 10 cm diameter culture dishes, 25 μg
plasmid DNA were diluted in 300 μl HBSS, supplemen-
ted with 120 μl Superfect (Qiagen), incubated for
15 minutes and diluted into 4.5 ml complete medium.
3 hours after transfection, cells were replated onto 24
well plates at 250,000 cells/well in 0.2 ml of complete
medium.
Compound treatments, cytotoxicity, and sample
preparation
Compounds were pre-diluted at the desired concentra-
tion in complete medium starting from 10 mM DMSO
stock solutions. 6 hours after DNA transfection and 3
hours after seeding the cells onto 24 well plates, 0.3 ml
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DMEM/FBS medium containing the test compounds
was added to the cells. For the primary screen, the
compounds were tested at a final dilution of 10 μM in
500 μl medium/well of the 24 well plates. Each plate
was used to test 7 compounds in triplicates and for a
vehicle (DMSO) control. 12 hours after start of the
compound treatment, the cells were supplemented with
a proteasome inhibitor to facilitate the detection of the
proteolysis cleavage products. For this, 1.25 μl of a 2
mM epoxomicin (Chemicon) stock solution in DMSO
was first diluted in batch with 8.75 μl of DMEM/FBS
per well, then 10 μl were added to the wells to reach a
final concentration of 5 μM epoxomicin. DMSO final
concentration was 0.035%.
Cytotoxicity was assessed visually 16 hours after start
of the compound treatment by observing the cells in
each well under a microscope. The presence of detached
or dead cells was indicative of cell toxicity. Cell lysates
were prepared 18 hours after start of the compound
treatment (24 hours post-transfection): culture medium
was aspirated and replaced by 60 μl/well in lysis buffer
(50 mM Tris pH 7.4, 250 mM NaCl, 5 mM EDTA, and
1% Nonidet NP40, with EDTA-free complete protease
inhibitor (Roche)). After 10 minutes on ice with shaking,
cells were scraped from the plates and transferred into a
fresh tube and kept frozen at -80°C until further analy-
sis. After thawing, the samples were centrifuged for
1 minute at 10,000 xg. The supernatants were collected,
supplemented with 0.25 × volume of 4 × sample buffer
(Invitrogen) with 0.1 M DTT (final) and boiled for
5 minutes. SDS-PAGE using E-PAGE-48 gels (Invitro-
gen) and western blot analysis were performed using
Ab1 (against aa1-17 of huntingtin). Western blots were
developed using SuperSignal West Pico stable Peroxide
Solution (Pierce) according to manufacturer’s instruc-
tions then exposed to film (Hyperfilm ECL, Amersham
Biosciences). Films were scanned on a Hewlett Packard
ScanJet 4C/T flat bed scanner acquired at 300 dpi using
Deskscan II and Adobe Photoshop software. Densitome-
try of images was performed using SigmaScan software
(Jandel Scientific) and statistical analysis was performed
using Excel and GraphPad Prism. Exposures in which
cpA and cpB could be easily detected in the control
lanes were used for analysis. Triplicate results from
compounds were compared to their respective controls
(run on the same 24 well plate) from the same
exposures.
Cell-free endoprotease digestion assay
The assay is a self-digestion assay [24] modified from
Lunkes et al, 2002 [23]. 50 μg protein from the 2000 ×g
pellet obtained from cells was homogenized in buffer
(20 mM Tris, 250 mM sucrose, 1 mM EDTA). The
assay buffer was 50 mM sodium citrate pH 3.5.
Reactions were incubated at 37°C for 60 minutes then
neutralized by addition of 6.7 N NH4OH prior to analy-
sis by SDS-PAGE and western blot. Compounds includ-
ing pepstatin A were tested at 10 μM for their ability to
inhibit the formation of small huntingtin fragments in
the range of cpA or cpB.
Construction of lentiviral vectors and AAV vectors
encoding huntingtin
Lenti-PGK-htt1-171 (18Q and 100Q): The cDNA
encoding 1-171 amino acids for both 18Q and 100Q
huntingtin were digested with BamH I and Xho I, then
sub-cloned into the corresponding sites of the pEN-
TR1A vector (Invitrogen). The pENTR1A 18Q and
100Q huntingtin 1-171 amino acid constructs were
digested with Nhe I and Xba I, while the lentiviral
CSCW2-PGK vector backbone was digested with Nhe I
and treated with calf alkaline phosphatase. The gel-
isolated inserts were sub-cloned into the CSCW2-PGK
vector. The vector also encoded an internal ribosome
binding site just 3’ to the huntingtin cDNA, followed by
the cDNA for GFP.
Lenti-CMV-htt1-400 (18Q and 100Q): The cDNA
encoding 1-400 amino acids for both 18Q and 100Q
huntingtin were digested with BamH I and PshA I,
while the pENTR1A vector (Invitrogen) was digested
with BamH I and Not I. Prior to ligation with insert, the
Not I site of the pENTR1A vector was blunt-ended with
Mung Bean Nuclease (New England Biolabs). The pEN-
TR1A 18Q and 100Q huntingtin 1-400 amino acid con-
structs were digested with BamH I and EcoR V, while
the CSCW2-hNoggin-IG vector (generous gift of Miguel
Esteves) was digested with Nhe I and treated with calf
alkaline phosphatase. Prior to ligation, the BamH I site
of the 1-400 amino acid inserts were blunt-ended with
Mung Bean Nuclease. The gel-isolated inserts were sub-
cloned into the CSCW2 vector. The vector also encoded
an internal ribosome binding site just 3’ to the hunting-
tin cDNA, followed by the cDNA for GFP. AAV-htt1-
400 (18Q and 100Q): The construction of the AAV vec-
tor driven by CBA promoter has been previously
described [11].
Lentiviral production
Lentiviral vectors were transfected into 293T cells using
FuGene 6 Reagent (Roche). Virus supernatant was iso-
lated by centrifugation at 24,000rpm for 90 minutes at
4°C. Lentiviral pellets were resuspended in PBS/0.5%
BSA solution. Virus titer was determined using RETRO-
tek HIV-1 p24 Antigen ELISA (ZMC).
AAV delivery into mouse striatum
The animal protocol in this study was approved by the
University of Massachusetts Medical School (A-978).
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Mice (C57B6) received microinjections by stereotactic
placement into the right striata of AAV-htt-400-18Q
(3 μl per striata, N = 4 mice) or AAV-htt-100Q unilater-
ally (3 μl per striata, N = 4 mice) using methods
previously described [11]. Mice were killed 3 days after
injection and the injected striata were harvested for
biochemical analysis.
Primary neuron culture
Timed-pregnant Sprague-Dawley rats (Charles Rivers
Laboratories) were sacrificed by CO2 inhalation and
embryos (embryonic day 19) were collected in a Petri
dish and placed on ice. Dissections were performed
under a stereomicroscope in ice cold dissection medium
(1× HBSS) containing 1 mM pyruvate, 0.6% D-glucose,
10 mM HEPES and 1% Pen-Strep. Cerebral cortices or
striata were isolated, cut into pieces using forceps, and
collected in a 15 ml Falcon tube. The tissue was homo-
genized by repeated pipetting with a fire-polished
Pasteur pipette in dissection medium. Cells were centri-
fuged at 4°C for 5 minutes at 1000 ×g and resuspended
in Neurobasal medium containing 2% B27, 1% Pen-Strep
and 2 mM L-Glutamine. 300,000 cells were plated per
well of 12-well plates coated with 50 μg/ml Poly-D-lysine.
On day in vitro (DIV) 1, the cultures were infected with
lentiviral vectors. Half of the medium was replaced with
fresh Neurobasal medium supplemented with 2% B27,
1% Pen-Strep and 2 mM L-Glutamine on DIV4 for cul-
tures maintained for several days. Primary rat neurons
were infected DIV 2 with Lenti-PGK-htt1-171-18Q or
100Q lentivirus at 80 multiplicity of infection (moi) or at
indicated moi then cultured for up to 2 weeks.
Pregnant mice (C57BL/6 strain background) were
obtained from Charles River Laboratories. The animal
protocol was reviewed and approved by the MGH Sub-
committee on Research Animal Care (SRAC)-OLAW
Assurance # A3596-01. The protocol was submitted and
reviewed conforms to the USD Animal Welfare Act,
PHS Policy on Humane Care and Use of Laboratory
Animals, the “ILAR Guide for the Care and Use of
Laboratory Animals” and other applicable laws and reg-
ulations. HD mice were of the same strain but had
human exon1 with an expanded polyQ (140Q) intro-
duced by homologous recombination into the endogen-
ous mouse allele [14]. Homozygous Q140/Q140 mice
were used to prepare cortical neuron cultures for the
toxicity assay.
Primary cortical neurons were obtained from brains of
embryonic mice (E15-E17) as described before [36].
Briefly, brains were dissected from embryos and after
meninges were removed, cortices were incubated at 37°
C for 15 min with 0.625% trypsin in Neurobasal media
(NBM, supplemented with B27 and N2, 500 μg/ml
streptomycin, 100 IU/ml of penicillin and 2 mM
L-glutamine, all from Invitrogen, Carlsbad, CA). Trypsin
was removed and Dulbecco’s Modified Eagle Medium
plus nutrient mix F12 (DMEM/F12, from Invitrogen)
supplemented with 10% fetal bovine serum (FBS from
Invitrogen), N2 supplement and penicillin/streptomycin
was added. Cortices were treated with 12.5 μg/ml of
DNAse I (Sigma, St. Louis, MO) in DMEM/F12 for
5 min at 37°C and homogenized. Cell suspension
was then diluted in NBM supplemented with 15 μM
L-glutamate and 10 μM 2-mercaptoethanol (Invitrogen).
Neurons were plated at 800,000 cells/ml in culture
dishes pre-coated with poly-L-lysine 0.2 mg/ml in borate
buffer pH 8.0 (30-70 kDa from Sigma) for 24 h followed
for 1 h coating period with 10% FBS (DMEM/F12 plus
10% FBS). Cytosine b-D-arabinofuranoside (AraC) was
added at second day in vitro (DIV) for 24 h, and then
media was completely replaced with fresh NBM. Half of
the volume of medium was replaced every third day. A
quantitative assessment using markers for neural cell
types including Beta III-tubulin for neurons, glial fibril-
lary acidic protein for astrocytes and cd68 for microglia
showed that the majority of cells are neurons (99.5%).
Primary mouse neurons were infected DIV 1 with Lenti-
PGK-htt1-171-18Q or 100Q lentivirus at 160 moi then
cultured for up to 2 weeks.
For compound treatment experiments, primary mouse
neurons were infected DIV 1 with Lenti-PGK-htt1-171-
18Q lentivirus at 160 moi. Ara C treatment was omitted.
After 8 hours, the cells were then treated with
compounds re-suspended in Neurobasal media to
appropriate concentrations and cultured for an addi-
tional 16 hours (24 hours for infection, 16 hours for
treatment). Cells were harvested 24 hours post-infection
in NP40 lysis buffer + protease inhibitor tablet. 12 μl of
lysate was loaded onto 4-12% Bis-Tris gels and analyzed
by western blot and densitometry analysis as described
above. Membranes were probed with Ab1 (0.5 μg/ml)
and Beta III-Tubulin (1:1000; Sigma).
SiRNA experiments
siRNA targeting cathepsin D (Dharmefect SmartPool)
and a control siRNA that does not target any known
sequence in the mouse genome (non-target) were
obtained from Dharmacon. SiRNAs were introduced to
primary neurons using Dharmafect reagent 1 (Thermo,
Inc). At DIV5, neurons were incubated for 1 hour with
antibiotic free Neurobasal medium before transfection
to acclimate cells to experimental conditions. 2.8 mL of
complete antibiotic free medium was added to com-
plexed Dharmafect/siRNA solution (siRNA final concen-
tration 20 nM) for a total volume of 3.5 mL and
incubated for 48 hours. Then neurons were harvested in
75-100 uL of lysis buffer (50 mM Tris, 250 mM NaCl, 5
mM EDTA, 1% NP40, pH 7.4) with mini-EDTA-free
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cocktail protease inhibitor tablet (Roche) and analyzed
by western blot using anti-cathepsin D antibody (Onco-
gene Scienece).
Immunoprecipitation
HD neurons were lysed in IP buffer (50 mM Tris pH
7.4, 250 mM NaCl, 1% NP40, 5 mM EDTA + protease
inhibitor tablet (Roche)). Insoluble material removed by
centrifugation at 14,000 ×g , protein levels of superna-
tants were determined by Bradford assay, and 1 mg per
protein condition was incubated with protein G sephar-
ose beads (GE Healthcare) plus monoclonal anti-htt1-17
(mAb2B7, [39]) overnight at 4°C. Sepharose beads were
washed 3 times in IP buffer then 1 time in PBS, then
bound protein was eluted by boiling in 75 μl sample
buffer (Invitrogen) + DTT and analyzed by western blot
using polyclonal anti-htt1-17 (Ab1). No primary anti-
body and buffer alone were run as controls.
Western blot analysis of brain lysates, primary neurons
and clonal striatal cell
Brains were removed 3 days after injection with
AAV-htt1-400-18Q or AAV-htt1-400-100Q and rapidly
frozen. The area around the injection site was dissected
on ice and homogenized in 10 volumes lysis buffer +
protease inhibitor. After incubating 10 minutes at RT,
lysates were centrifuged at 10,000 ×g for 2 minutes and
the protein concentration of the supernatant was deter-
mined using the Bradford assay. 20 μg of protein was
separated by SDS-PAGE on 4-12% Bis-Tris, 4-20%
Tris-glycine or 3-8% Tris-acetate gels (Invitrogen) and
analyzed by western blot using anti-huntingtin antibody
Ab1 (made against huntingtin aa1-17) at 0.5 μg/mL,
anti-cathepsin D antibody (Oncogene Science ) at 2.5
μg/ml, anti-cathepsin E antibody (R&D Systems) at 0.2
μg/ml or anti-bIII tubulin (Sigma) at 1:1000.
Gamma-Secretase Assay
Huntingtin 1-171-18Q with an N-terminal FLAG-tag
(Fhtt171-18Q) was translated in vitro (TNT T7 Quick
Coupled Transcription/Translation System, Promega)
then immunopurified with M2-speharose (Sigma) and
eluted with TBS pH 7.1 as described previously [43]. The
CHAPSO-soluble membrane fraction was prepared
according to Li et al. [35] from SY5Y cells which are
reported to contain all four components of gamma-secre-
tase complex [34]. In vitro digestions contained equal
volumes of purified huntingtin 1-171-18Q and 50 mM
PIPES pH6.8, 5 mM MgCl2, 5 mM CaCl2, 150 mM KCl,
0.25% CHAPSO buffer. The CHAPSO-soluble membrane
fraction was added at 125 μg/ml with and without 1 μM
DAPT. Reactions were incubated for 2 hours or 5 hours
at 37°C then stopped with SDS-PAGE sample buffer and
analyzed by SDS-PAGE and western blot.
Additional material
Additional file 1: Figures S1-S5. Results from the initial screen in clonal
striatal X57 cells for small compounds that reduce levels of cpA or cpB
are shown in graphical form in Figure S1. In Figure S2, select compounds
were tested using an in vitro self-digestion assay of wild-type and
mutant huntingtin fragments. Figure S3 shows protein levels of
cathepsin D & E in cells and in brain. Figure S4 shows cathepsin D
protein levels after mRNA silencing and a lack of effect on cpA
production in lentivirus infected primary neurons. Finally, Figure S5
shows that treatment with the gamma-secretase inhibitor DAPT reduced
levels of small huntingtin fragments in Q140/Q140 knock-in mice,
correlating with increased survival.
Additional file 2: Table S1. Compounds that reached < 50% and/or
p < 0.05 for cpA and cpB in clonal striatal cells. This table
summarizes all positive hits from the initial screen in clonal striatal X57
cells expressing exogenous huntingtin 1-287-18Q for small compounds
that reduce levels of cpA or cpB. The data for all compounds tested is
shown in graphic form in Additional file 2.
Abbreviations
AAV: adeno-associated virus; cpA: cleavage product A; cpB: cleavage product
B; HD: Huntington disease; htt: huntingtin.
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